Aim New treatments have improved survival rate in CDH infants in comparison with past decades. However this better survival has raised concern about the long term morbidity, particularly in the first few years of life. Aim of our study is to evaluate the role of a multidisciplinary follow up for high risk CDH survivors.
Methods All high risk CDH survivors consecutively treated between 2004 and 2007 were included into our follow-up clinics. Prevalence of late morbidity was prospectively evaluated at 6 months, 1 and 2 years. Clinical examinations included auxological, gastro-intestinal, pulmonary, orthopedic and audiological evaluation. Comparison of prevalences at various ages was performed with the McNemar test.
Results 44 patients were enrolled into our follow-up program. Main results are summarized in the table.
Conclusion CDH survivors may present late morbidity. Our results highlight the importance of a multidisciplinary long term follow up to limit sequelae. Particularly, oral aversion and orthopedic disorders significantly increase with the age in our series, recommending a long term evaluation. More studies are needed to better understand the role of new treatments in the development of late morbidity in CDH survivors.